JAK2 V617F -CZEMP

E.A. Rodrigo, A.A.-Larrán, J.C. Reverter, N. Villamor, D. Colomer , F. Cervantes

Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status

Haematologica 2006; 91: 169-175

C. Bellanné-Chantelot, I. Chaumarel, M. Labopin, F. Bellanger, V. Barbu, C. De Toma

Genetic and clinical implications of the Val617Phe JAK2 mutation in72 families with myeloproliferative disorders

Blood 2006; 108: 346-352

P. J. Campbell, M. Griesshammer, K. Do¨hner, H. Do¨hner, R. Kusec, H. C. Hasselbalch

V617F mutation in JAK is associated with poorer survival in idiopathic myelofibrosis

Blood 2006; 107: 2098-2100

V.DE STEFANO, A. FIORINI, E. ROSS I , T. ZA, G. FARINA, P. CHIUSOLO

Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders  

Journal of Thrombosis and Haemostasis 2007; 5: 708–714

J. Jelinek, Y. Oki, V. Gharibyan, C. Bueso-Ramos, J. T. Prchal, S. Verstovsek

JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML,Philadelphia,

chromosome-negative CML,and megakaryocytic leukemia

Blood 2005; 106: 3370-3373

Xuesong Xu, Qi Zhang, Jian Luo, Shu Xing, Qingshan Li, Sanford B. Krantz

JAK2V617F:prevalence in a large Chinese hospital population 

Blood 2007; 109: 339-342

F. Delhommeau, S. Dupont, C.Tonetti, A. Masse´ ,I. Godin, J.P. Le Couedic

Evidence that the JAK2 G1849T (V617F) mutation occurs in a progenitor in polycythemia vera and idiopathic myelofibrosis

Blood 2007; 109: 71-77

D. P. Steensma, G.W. Dewald, T. L. Lasho, H. L. Powell, R. F. McClure, R. L. Levine

The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes

Blood 2005; 106: 1207-1209

R.Kralovics, F. Passamonti, A. S. Buser,S.S. Teo, R. Tiedt,  J.R. Passweg

A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders

The New England Journal of Medicine 2005; 352: 1779-90

C. Lacout, D. F. Pisani, M. Tulliez, F. M. Gachelin, W. Vainchenker,J.L. Villeval

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis

Blood 2006; 108: 1652-1660

J. MARKOVA, D. PRUKOVA, Z. VOLKOVA, J.SCHWARZ

A new allelic discrimination assay using locked nucleic acid-modified nucleotides (LNA) probes for detection of JAK2V617F mutation

Leukemia & Lymphoma, March 2007; 48(3): 636 – 639

M. J. Percy, F.G.C. Jones, A.R. Green, J.T. Reilly, M.F. McMullin

The incidence of JAK2V617F mutation in patients with idiopathic erythrocytosis 

Haematologica 2006; 91: 413-414

M.J. Percy,  L. M. Scott, W. N. Erber, C. N. Harrison, J. T. Reilly, F. G.C. Jones

The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels

Haematologica 2007; 92: 1607-1614

F. X. Schaub, R. Jager, R. Looser, H. H.-Shen, S. Hermouet, F.Girodon

Clonal analysis of deletions on chromosome 20q and JAK2-V617F in MPD suggests that del 20q acts independently and not one of the predisposing mutations for JAK2-V617F

Blood 2009; 113: 2022-2027

_{A.Tefferi,T. L. Lasho, G. Gilliland, R. Kralovics, M. Cazzola,R. C. Skoda}

JAK2 Mutations in Myeloproliferative Disorders

The New England Journal of Medicine 2005; 353: 1416-1417